Vitamin K at Birth
The Shot That Prevents Brain Bleeds
Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.
Overwhelming guideline consensus and long observational record support grade 5. The AAP 2022 policy statement 'Vitamin K and the Newborn Infant' (Pediatrics 149(3):e2021056036) recommends a single 1 mg intramuscular dose within six hours of birth for all newborns over 1500 g and states plainly that oral prophylaxis is not as effective against late VKDB and cannot be recommended; the WHO, UK NHS and NICE, and the Canadian Paediatric Society give the same intramuscular recommendation. VKDB became rare wherever the intramuscular shot was routine after the 1961 AAP recommendation, and incidence rises where prophylaxis is declined. The harm from refusal is documented: the CDC-investigated 2013 Tennessee cluster (MMWR 62(45)) saw four previously healthy infants bleed at 6 to 15 weeks, three with intracranial hemorrhage, all after parents declined; a December 2025 JAMA analysis of over 5 million births (DOI 10.1001/jama.2025.21460) found non-receipt rose 77%, from 2.92% in 2017 to 5.18% in 2024. The 1992 Golding BMJ leukemia signal was not replicated: Roman et al 2002 (British Journal of Cancer), pooling individual data from six case-control studies with 2,431 cases and 6,338 controls, found no convincing evidence that intramuscular vitamin K is associated with childhood leukemia.
- FDA
- Vitamin K1 injection is standard, recommended newborn care; not a vaccine
- WADA
- Not prohibited
Reference only. Not medical advice.
What can go wrong
The intramuscular injection is well established as safe across more than 60 years of routine use; the documented risk lies in declining it. US hospital refusal ranges from 0 to about 3.2% but reaches higher at home births and birthing centers, and a 2025 JAMA analysis of over 5 million births found non-receipt rose from 2.92% in 2017 to 5.18% in 2024, sharpest after 2020. Higher refusal is associated with more VKDB and intracranial hemorrhage in otherwise healthy babies, as the CDC-investigated 2013 Tennessee cluster showed. Oral regimens are less effective and depend on completing every dose. This is educational, not medical advice; any questions or concerns about vitamin K should be discussed with the baby's pediatrician or neonatologist, ideally before birth.
Newborns are born with very little vitamin K and breast milk supplies little, so without prophylaxis some infants develop vitamin K deficiency bleeding (VKDB), unpredictable hemorrhage that can include bleeding in the brain and cause death or lasting neurological harm. A single intramuscular vitamin K injection at birth prevents it, which is why the AAP has recommended it since 1961 and reaffirmed it in 2022, with the WHO and the Canadian Paediatric Society in agreement. Part of the dose acts quickly and the rest is stored and released over the following months. It is not a vaccine; it is a nutrient newborns are deficient in. Oral vitamin K is an alternative but is less effective, especially against late VKDB, and requires completing multiple doses. This is among the best-established interventions in all of newborn care.
Babies are born with almost no vitamin K, and a single injection at birth prevents a rare but devastating bleeding disorder, including bleeding in the brain.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
What people get wrong
Often saidThe vitamin K shot is unnecessary for a healthy baby from an uncomplicated birth.
ActuallyVKDB strikes otherwise healthy, full-term babies, and this belief is among the most common reasons parents decline. In the CDC-investigated 2013 Tennessee cluster, all four affected infants had been healthy and developing normally until sudden bleeding at 6 to 15 weeks; three had intracranial hemorrhage (CDC MMWR 62(45)).
Often saidThe vitamin K shot causes childhood leukemia.
ActuallyThis traces to a single 1992 Golding study in the BMJ that reported a signal. It was not replicated; a pooled analysis of individual data from six case-control studies (Roman, British Journal of Cancer, 2002; 2,431 cases and 6,338 controls) found no convincing evidence that intramuscular vitamin K is associated with childhood leukemia.
Often saidVitamin K is a vaccine, or you can skip it and just give oral drops that work just as well.
ActuallyVitamin K is a nutrient newborns are born deficient in, not a vaccine. Oral regimens are less effective against late VKDB and depend on completing multiple doses; the CPS notes an infant given oral prophylaxis still remains at risk for late VKDB, potentially with intracranial hemorrhage.
Who profits, and who pushes back
American Academy of Pediatrics
All newborns should receive a single intramuscular dose of vitamin K1 (0.5-1 mg) within the first 6 hours of birth to prevent vitamin K deficiency bleeding; the injection is more effective than oral regimens.
World Health Organization & Canadian Paediatric Society
Routine newborn vitamin K prophylaxis is recommended; intramuscular administration is preferred, with multiple oral doses only as an alternative.
Pediatric hematology surveillance (2025)
Refusal of intramuscular vitamin K is rising worldwide, paralleling vaccine hesitancy, and is associated with increases in VKDB and intracranial hemorrhage; parental concerns are often based on disproven claims.
Vitamin K refusal movement
A minority of parents decline the shot citing a desire for a "natural" birth, injection-pain concerns, the debunked cancer link, or the false belief it is a vaccine, positions not supported by the evidence.
Where the research comes from
Most of the published research on this comes from one place. 97% of it is from Receiving the shot. Findings that no unrelated group has reproduced are weaker than the study count makes them look.
| Place | Share of published research |
|---|---|
| Receiving the shot | 97% |
| US hospital refusal 0-3.2% | 3% |
Research published from: Global.
How we got here
Newborn bleeding was described by the Boston physician Charles Townsend in 1894 as 'hemorrhagic disease of the newborn,' but its cause stayed unknown until the Danish scientist Henrik Dam identified a fat-soluble clotting factor in 1929 and named it vitamin K, from Koagulation; Dam shared the 1943 Nobel Prize with Edward Doisy, who worked out its structure. Once deficiency was linked to newborn bleeding, the American Academy of Pediatrics recommended prophylaxis for all newborns in 1961, and the disease became rare wherever the shot was routine. The legacy label 'hemorrhagic disease of the newborn' was later replaced by 'vitamin K deficiency bleeding' to name the cause, and the AAP reaffirmed intramuscular prophylaxis in its 2022 policy statement.
Newborn bleeding was described long before its cause was understood. In 1894 the Boston physician Charles Townsend reported 50 cases of what he called hemorrhagic disease of the newborn, noting it appeared in the first days of life, lacked a family history and was self-limiting, distinguishing it from hemophilia. The mechanism stayed a mystery until the Danish scientist Henrik Dam, studying bleeding in chickens on fat-free diets, identified a fat-soluble clotting factor in 1929 and named it vitamin K, from Koagulation, the Danish and German word for coagulation; Dam shared the 1943 Nobel Prize in Physiology or Medicine with Edward Doisy, who determined its chemical structure. Once vitamin K linked deficiency to newborn bleeding, prophylaxis followed, and in 1961 the American Academy of Pediatrics recommended it for all newborns. VKDB became rare wherever the shot was routine.
- 1894Charles Townsend in Boston describes 50 cases of hemorrhagic disease of the newborn
- 1929Henrik Dam identifies vitamin K in chicks on fat-free diets; names it for Koagulation
- 1943Dam and Edward Doisy share the Nobel Prize in Physiology or Medicine for vitamin K
- 1961AAP first recommends newborn vitamin K prophylaxis for all infants
- 1992Golding BMJ case-control study reports an intramuscular vitamin K to childhood leukemia signal
- 2002Roman pooled analysis of six case-control studies finds no convincing leukemia association
- 2013CDC MMWR reports a Tennessee cluster of four late-VKDB infants whose parents declined the shot
- 2022AAP reaffirms intramuscular vitamin K for all newborns in an updated policy statement
- 2025JAMA analysis of over 5 million US births finds non-receipt rose from 2.92% (2017) to 5.18% (2024)
At a glance
- AAP dose
- 0.5-1 mg IM, within 6 hours
- Recommended since
- 1961
- Without it (classic VKDB)
- Up to ~1.5% historically
- Injection vs oral
- IM more effective
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Vitamin K at Birth. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
AAP 2022 policy recommends a single 1 mg intramuscular vitamin K dose for all newborns over 1500 g within six hours of birth and states oral prophylaxis is less effective against late VKDB and cannot be recommended.
American Academy of Pediatrics, 'Vitamin K and the Newborn Infant,' Pediatrics 149(3):e2021056036
AAP news summary: incidence of VKDB is increasing, largely attributable to parental declination and use of less effective alternative regimens; late-onset VKDB often presents with intracranial bleeding.
AAP News, 'Vitamin K policy addresses birth dose for term, preterm infants; parental concerns'
Parent-facing AAP guidance: newborns need vitamin K shortly after birth to prevent VKDB, a rare but serious bleeding disease.
HealthyChildren.org (AAP), 'Newborns Need Vitamin K Shortly After Birth to Prevent Bleeding Disease'
Non-receipt of newborn vitamin K rose 77%, from 2.92% in 2017 to 5.18% in 2024, across more than 5 million births, signaling rising parental refusal with public health implications.
Four previously healthy infants developed late VKDB at 6 to 15 weeks after parents declined intramuscular vitamin K; three had intracranial hemorrhage, one later had a gross motor deficit.
Pooled individual-patient analysis of six case-control studies (2,431 cases, 6,338 controls) found no convincing evidence that intramuscular vitamin K is associated with childhood leukemia, refuting the 1992 Golding signal.
Independent large cohort (Klebanoff et al.) found no increased childhood cancer risk after neonatal vitamin K exposure, an early non-replication of Golding.
United Kingdom Childhood Cancer Study reported no evidence that intramuscular vitamin K raises the risk of childhood cancer overall.
WHO recommends 1 mg intramuscular vitamin K within six hours of birth for all newborns to prevent VKDB.
UK NHS offers a single 1 mg intramuscular vitamin K injection at birth to prevent VKDB (formerly haemorrhagic disease of the newborn), with a multi-dose oral schedule as a less-preferred alternative; recommended by the Department of Health and NICE.
University College London Hospitals NHS Foundation Trust, 'Vitamin K for Babies at Birth'
Review of parental refusal characterizes drivers and confirms oral regimens are less effective against late VKDB, which frequently presents with intracranial hemorrhage.